Loading clinical trials...
Loading clinical trials...
The purpose of this study was to assess the efficacy and safety of vildagliptin 50 mg bid add-on therapy to improve overall glycemic control in patients with T2DM inadequately controlled by insulin, w...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07023406 · Type 2 Diabetes Mellitus (T2DM)
NCT06613854 · Type 2 Diabetes Mellitus (T2DM)
NCT06821399 · Diabetes, Diabetic Retinopathy, and more
NCT06810635 · Type 2 Diabetes Mellitus (T2DM)
NCT07051005 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)
Novartis Investigative Site
Fukuoka, Fukuoka
Novartis Investigative Site
Fukuoka, Fukuoka
Novartis Investigative Site
Fukutsu, Fukuoka
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions